IVIG Trial for the Treatment of Bronchopulmonary Dysplasia

Recruiting now · Phase 2

Conditions studied: Bronchopulmonary Dysplasia

In brief

It is intended to examine the efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.

Key facts

Study ID
NCT06925360
Run by
International Peace Maternity and Child Health Hospital
People needed
20
Starts
2025-04-12
Expected to finish
2027-12-01
Last updated by the study team
2026-05-27

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.